The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2018
Filed:
Nov. 08, 2013
Applicant:
Whitehead Institute for Biomedical Research, Cambridge, MA (US);
Inventors:
Wai Leong Tam, Singapore, SG;
Robert A. Weinberg, Brookline, MA (US);
Assignee:
Whitehead Institute for Biomedical Research, Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 45/06 (2006.01); C12N 15/113 (2010.01); C12N 5/09 (2010.01); G01N 33/50 (2006.01); A61K 31/404 (2006.01); A61K 31/506 (2006.01); A61K 31/7105 (2006.01); A61K 31/713 (2006.01); A61K 31/337 (2006.01); A61K 31/403 (2006.01); A61K 31/4045 (2006.01); A61K 31/437 (2006.01); A61K 31/553 (2006.01); A61K 31/704 (2006.01); A61K 38/08 (2006.01); A61N 5/10 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0693 (2013.01); A61K 31/337 (2013.01); A61K 31/403 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/437 (2013.01); A61K 31/506 (2013.01); A61K 31/553 (2013.01); A61K 31/704 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 38/08 (2013.01); A61K 45/06 (2013.01); A61N 5/10 (2013.01); C12N 15/113 (2013.01); G01N 33/5011 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2320/31 (2013.01); C12N 2501/727 (2013.01);
Abstract
Aspects of the invention relate to methods and related compositions for preferentially targeting cancer stem cells. In some embodiments, the methods utilize PKC-α/FRA1 pathway inhibitors to target carcinoma cells. Also provided are methods for identifying a candidate compound for selectively inhibiting growth of cancer stem cell, and methods for obtaining cells that have undergone an epithelial to mesenchymal transition.